ALPL | Alkaline phosphatase, liver/bone/kidney | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ALPP | Alkaline phosphatase, placental | Cancer-related genes Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
ALPPL2 | Alkaline phosphatase, placental-like 2 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AMBP | Alpha-1-microglobulin/bikunin precursor | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
AMELX | Amelogenin, X-linked | Disease related genes Predicted secreted proteins
| | | | | Not detected |
AMELY | Amelogenin, Y-linked | Predicted secreted proteins
| | | | | Not detected |
AMH | Anti-Mullerian hormone | Disease related genes Predicted secreted proteins
| | | | | Group enriched |
AMICA1 | Adhesion molecule, interacts with CXADR antigen 1 | Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
AMPD1 | Adenosine monophosphate deaminase 1 | Disease related genes Enzymes Potential drug targets Predicted secreted proteins
| | | | | Tissue enriched |
AMTN | Amelotin | Predicted secreted proteins
| | | | | Group enriched |
AMY1A | Amylase, alpha 1A (salivary) | Enzymes Predicted secreted proteins
| | | | | Group enriched |
AMY1B | Amylase, alpha 1B (salivary) | Enzymes Predicted secreted proteins
| | | | | Group enriched |
AMY1C | Amylase, alpha 1C (salivary) | Enzymes Predicted secreted proteins
| | | | | Group enriched |
AMY2A | Amylase, alpha 2A (pancreatic) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
AMY2B | Amylase, alpha 2B (pancreatic) | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
ANAPC2 | Anaphase promoting complex subunit 2 | | | | | | Expressed in all |
ANGEL1 | Angel homolog 1 (Drosophila) | Predicted secreted proteins
| | | | | Expressed in all |
ANGPT1 | Angiopoietin 1 | Cancer-related genes Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
ANGPT2 | Angiopoietin 2 | Cancer-related genes Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
ANGPT4 | Angiopoietin 4 | Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ANGPTL1 | Angiopoietin-like 1 | Predicted secreted proteins
| | | | | Mixed |
ANGPTL2 | Angiopoietin-like 2 | Predicted secreted proteins
| | | | | Mixed |
ANGPTL3 | Angiopoietin-like 3 | Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
ANGPTL4 | Angiopoietin-like 4 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ANGPTL5 | Angiopoietin-like 5 | Predicted secreted proteins
| | | | | Tissue enriched |
ANGPTL6 | Angiopoietin-like 6 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ANK1 | Ankyrin 1, erythrocytic | Cytoskeleton related proteins Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ANKIB1 | Ankyrin repeat and IBR domain containing 1 | Predicted secreted proteins
| | | | | Expressed in all |
ANKLE1 | Ankyrin repeat and LEM domain containing 1 | Predicted membrane proteins
| | | | | Tissue enriched |
ANKRD60 | Ankyrin repeat domain 60 | Predicted secreted proteins
| | | | | Tissue enriched |
ANKS6 | Ankyrin repeat and sterile alpha motif domain containing 6 | Disease related genes
| | | | | Mixed |
ANO7 | Anoctamin 7 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ANTXR1 | Anthrax toxin receptor 1 | Disease related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
AOAH | Acyloxyacyl hydrolase (neutrophil) | Enzymes Predicted secreted proteins
| | | | | Mixed |
AOC1 | Amine oxidase, copper containing 1 | Enzymes Predicted secreted proteins
| | | | | Group enriched |
AOC2 | Amine oxidase, copper containing 2 (retina-specific) | Enzymes Predicted secreted proteins
| | | | | Group enriched |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AP000721.4 | Uncharacterized protein | Predicted secreted proteins
| | | | | Not detected |
AP4E1 | Adaptor-related protein complex 4, epsilon 1 subunit | Disease related genes Plasma proteins
| | | | | Expressed in all |
APBB1 | Amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) | Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
APBB2 | Amyloid beta (A4) precursor protein-binding, family B, member 2 | | | | | | Expressed in all |
APCDD1 | Adenomatosis polyposis coli down-regulated 1 | Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
APCS | Amyloid P component, serum | Disease related genes Plasma proteins Potential drug targets Predicted secreted proteins Transporters
| | | | | Tissue enriched |
APLP1 | Amyloid beta (A4) precursor-like protein 1 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
APLP2 | Amyloid beta (A4) precursor-like protein 2 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
APMAP | Adipocyte plasma membrane associated protein | Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
APOA1 | Apolipoprotein A-I | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
APOA1BP | Apolipoprotein A-I binding protein | Enzymes Predicted secreted proteins
| | | | | Expressed in all |
APOA2 | Apolipoprotein A-II | Cancer-related genes Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
APOA4 | Apolipoprotein A-IV | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |